

John Mendelsohn, M.D.
President, M. D. Anderson Cancer Center

Publications

Articles in Peer-Reviewed Journals

1. **Mendelsohn J**, Tissieres A. Variations in the amount of ribonucleo-protein particles in *Escherichia coli*. *Biochem Biophys Acta* 35:248-250, 1959.
2. Salzman NP, Moore DE, **Mendelsohn J**. Isolation and characterization of human metaphase chromosomes. *Proc Natl Acad Sci USA* 56:1449-1456, 1966.
3. **Mendelsohn J**, Moore DE, Salzman NP. Separation of isolated Chinese hamster metaphase chromosomes into three size-groups. *J Mol Biol* 32:101-112, 1968.
4. Dawson DM, Alper CA, Seidman J, **Mendelsohn J**. Measurement of serum enzyme turnover rates. *Ann Intern Med* 70:799-805, 1969.
5. **Mendelsohn J**, Skinner SA, Kornfeld. The rapid induction by phytohemagglutinin of increased alpha-aminoisobutyric acid uptake by lymphocytes. *J Clin Invest* 50:818-826, 1971.
6. Rosenfeld MG, Abrass IB, **Mendelsohn J**, Roos BA, Boone RF, Garren LD. Control of transcription of RNA rich in polyadenylic acid in human lymphocytes. *Proc Natl Acad Sci USA* 69:2306-2311, 1972.
7. **Mendelsohn J**, Multer MM, Boone RF. Enhanced effects of prostaglandin E₁ and dibutyryl cyclic AMP upon human lymphocytes in the presence of cortisol. *J Clin Invest* 52:2129-2137, 1973.
8. Rosenfeld M, Abrass IB, **Mendelsohn J**, Miller H. Poly(A): possible role in translation of poly(A)-rich RNA. *Proc Soc Exp Biol Med* 144:215-219, 1973.
9. Fox RM, **Mendelsohn J**, Barbosa E, Goulian M. RNA in nascent DNA from cultured human lymphocytes. *Nature New Biol* 245:234-237, 1973.
10. Wong-Staal F, **Mendelsohn J**, Goulian M. Ribonucleotides in closed circular mitochondrial DNA from HeLa cells. *Biochem Biophys Res Commun* 53:140-148, 1973.
11. **Mendelsohn J**, Fox RM, Goulian M, Barbosa E. Nascent DNA from phytohemagglutinin stimulated human lymphocytes. *Immunol Commun* 4:373-385, 1975.

12. **Mendelsohn J**, Castagnola JM, Goulian M. On the mechanisms for formation of RNA-DNA complexes from lymphocytes. *Biochem Biophys Acta* 407:283-291, 1975.
13. Snyder FF, **Mendelsohn J**, Seegmiller JE. Adenosine metabolism in phytohemagglutinin-stimulated human lymphocytes. *J Clin Invest* 58:654-666, 1976.
14. **Mendelsohn J**, Multer MM, Bernheim JL. Inhibition of human lymphocyte stimulation by steroid hormones: cytokinetic mechanisms. *Clin Exp Immunol* 27:127-134, 1977.
15. Bernheim JL, **Mendelsohn J**, Kelley MF, Dorian R. Kinetics of cells death and disintegration in human lymphocyte cultures. *Proc Natl Acad Sci USA* 74:2536-2540, 1977.
16. Linthicum DS, Elson E, **Mendelsohn J**, Sell S. Endocytosis and exocytosis of phytohemagglutinin cell surface receptors of human lymphocytes during blast transformation. *Exp Cell Res* 110:237-250, 1977.
17. Dorian R, Bernheim JL, **Mendelsohn J**. Quantification of entry into and exit from the cell cycle in human lymphocyte cultures. *Cell Tissue Kinet* 11:33-44, 1978.
18. Shiftan TA, Caviles Jr AP, **Mendelsohn J**. Spontaneous lymphocyte proliferation and depressed cellular immunity in Hodgkin's disease. *Clin Exp Immunol* 32:144-152, 1978.
19. Bernheim JL, Dorian R, **Mendelsohn J**. DNA synthesis and proliferation of human lymphocytes in vitro: II. Cell kinetics of response to phytohemagglutinin. *J Immunol* 120:955-962, 1978.
20. Bernheim JL, Dorian R, **Mendelsohn J**. DNA synthesis and proliferation of human lymphocytes in vitro: II. Characterization of the DNA newly synthesized after phytohemagglutinin stimulation. *J Immunol* 120:963-970, 1978.
21. Shiftan TA, **Mendelsohn J**. The circulating "atypical" lymphocyte. *Hum Pathol* 9:51-61, 1978.
22. Shiftan TA, **Mendelsohn J**. Hodgkin's disease and anergy. *Blut* 38:1-7, 1979.
23. de Vries JE, Caviles Jr AP, Bont WS, **Mendelsohn J**. The role of monocytes in human lymphocyte activation by mitogens. *J Immunol* 122:1099-1107, 1979.
24. **Mendelsohn J**, Nordberg J. Adenylate cyclase in thymus-derived and bone marrow-derived lymphocytes from normal donors and patients with chronic lymphocytic leukemia. *J Clin Invest* 63:1124-1132, 1979.

25. Taetle R, Lane TA, **Mendelsohn J**. Drug induced agranulocytosis: in vitro evidence for immune suppression of granulopoiesis and a cross-reacting lymphocyte antibody. *Blood* 54:501-512, 1979.
26. Newman JG, Newman TB, Bowie LJ, **Mendelsohn J**. An examination of the role of vitamin E in glucose-6-phosphate dehydrogenase deficiency. *Clin Biochem* 12:149-151, 1979.
27. **Mendelsohn J**, Howell SB. Thymidine (TdR) as a potential chemotherapeutic agent: cytokinetic studies. *Acta Microbiol Scand* 274:509-510, 1980.
28. de Vries JE, **Mendelsohn J**, Bont WS. Requirement for monocytes in the spontaneous cytotoxic effects of human lymphocytes against non-lymphoid target cells. *Nature* 283:574-576, 1980.
29. de Vries JE, **Mendelsohn J**, Bont WS. The role of target cells, monocytes and Fc receptor bearing lymphocytes in human spontaneous cell mediated cytotoxicity and antibody dependent cytotoxicity. *J Immunol* 125:396-405, 1980.
30. Howell SB, Chu B, **Mendelsohn J**, et al. Thymidine as a chemotherapeutic agent: pharmacologic, cytokinetic, and biochemical studies in a patient with T-cell acute lymphocytic leukemia. *J Natl Cancer Inst* 65:277-284, 1980.
31. Howell SB, Taetle R, **Mendelsohn J**. Thymidine as a chemotherapeutic agent: sensitivity of normal human marrow, peripheral blood T cells, and acute nonlymphocytic leukemia. *Blood* 55:505-510, 1980.
32. Green MH, Brooks TL, **Mendelsohn J**, Howell SB. Antitumor activity of L-Canavanine against L1210 murine leukemia. *Cancer Res* 40:535-537, 1980.
33. Byfield JE, Barone RM, **Mendelsohn J**, et al. Infusional 5-fluorouracil and X-ray therapy for non-resectable esophageal cancer. *Cancer* 45:703-708, 1980.
34. de Vries JE, **Mendelsohn J**, Bont WS. The requirement for monocytes in spontaneous cytotoxicity by lymphocytes from healthy donors and melanoma patients. *Int J Cancer* 25:73-84, 1980.
35. Taetle R, **Mendelsohn J**. Modulation of normal and abnormal myeloid progenitor proliferation by cyclic nucleotides and PGE. *Blood Cells* 6:701-718, 1980.
36. Taetle R, Guittard JP, **Mendelsohn J**. Abnormal modulation of granulocyte/macrophage progenitor proliferation by prostaglandin E in chronic myeloproliferative disorders. *Exp Hematol* 8:1190-1201, 1980.

37. **Mendelsohn J**, Hudig D, Castagnola JM. DNA synthesis and proliferation of human lymphocytes in vitro: III. Fate of cycling cells in aging cultures of phytohemagglutinin stimulated human lymphocytes. *J Cell Physiol* 106:13-22, 1981.
38. de Vries JE, Vyth-Dreese FA, **Mendelsohn J**. T-cell growth factor mediated proliferation of lymphocytes from a T-chronic lymphocytic leukemia patient lacking mitogen and alloantigen responsiveness. *Clin Exp Immunol* 43:302-310, 1981.
39. Howell SB, Chu BF, Wung WE, Mehta BM, **Mendelsohn J**. Long duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. *J Clin Invest* 67:1161-1170, 1981.
40. Hudig D, Djobadze M, Redelman D, **Mendelsohn J**. Active tumor cell resistance to human natural killer (NK) lymphocyte attack. *Cancer Res* 41:2803-2808, 1981.
41. Rice C, Hudig D, Newton RS, **Mendelsohn J**. Effect of unsaturated fatty acids on human lymphocytes: disparate influences of oleic and linolenic acids on natural cytotoxicity. *J Clin Immunol Immunopathol* 20:389-401, 1981.
42. Hudig D, Haverty T, Fulcher C, Redelman D, **Mendelsohn J**. Inhibition of human natural cytotoxicity by macromolecular antiproteases. *J Immunol* 126:1569-1574, 1981.
43. Taetle R, **Mendelsohn J**. An emerging role for prostaglandin E₁ in regulation of granulopoiesis. *Leuk Res* 5:511-512, 1981.
44. Taetle R, Richardson D, To D, Royston I, **Mendelsohn J**. Colony-forming assay for circulating chronic lymphocytic leukemia cells. *Leuk Res* 6:335-344, 1982.
45. Rice J, **Mendelsohn J**. Deconvolution of microfluorometric histograms with -splines. *J Am Stat Assoc* 77:748-753, 1982.
46. Dillman RO, Taetle R, Seagren S, Royston I, Koziol J, **Mendelsohn J**. Extensive disease small cell carcinoma of the lung. Trial of non-cross resistant chemotherapy and consolidation radiotherapy. *Cancer* 49:2003-2008, 1982.
47. Dillman RO, Beauregard JC, **Mendelsohn J**, Green MR, Howell SB, Royston I. Phase I trials of thymosin fraction 5 and thymosin I. *Journal of Biological Response Modifiers* 1:35-41, 1982.
48. Young J, Dillman RO, Seagren SL, et al. Non-cross resistant chemotherapy and consolidation radiotherapy for small cell carcinoma of the lung. *Cancer Treatment Reports* 66:1339-1401, 1982.

49. Taetle R, To D, Caviles A, Norby S-W, **Mendelsohn J**. Characterization of normal, peripheral blood lymphocyte colony-forming cells: Cell cycle status, surface markers, cellular growth requirements. *Blood* 61:548-555, 1983.
50. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, **Mendelsohn J**. Growth stimulation of A431 cells by EGF: Identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. *Proc Natl Acad Sci USA* 80:1337-1341, 1983.
51. **Mendelsohn J**, Trowbridge IS, Castagnola JM. Inhibition of human lymphocyte proliferation by monoclonal antibody to transferrin receptor. *Blood* 62:821-826, 1983.
52. Sato JD, Kawamoto T, Le AD, **Mendelsohn J**, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human EGF receptors. *Mol Biol Med* 1:511-529, 1983.
53. Rice C, Hudig D, Lad P, **Mendelsohn J**. Ethanol activation of human natural cytotoxicity. *J Immunopharmacology* 6:303-316, 1983.
54. Gill GN, Kawamoto T, Cochet C, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. *J Biol Chem* 259:7755-7760, 1984.
55. Fagnani R, Cooper HL, **Mendelsohn J**. Purification of human Interleukin 2 homogeneity and partial characterization of its receptor. *Anal Biochem* 142:487-496, 1984.
56. Masui H, Kawamoto T, Sato JD, Wolf B, Sato GH, **Mendelsohn J**. Growth inhibition of human tumor cells in athymic mice by anti-EGF receptor monoclonal antibodies. *Cancer Res* 44:1002-1007, 1984.
57. Kawamoto T, **Mendelsohn J**, Le A, Sato GH, Lazar CS, Gill G. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. *J Biol Chem* 259:7761-7766, 1984.
58. Gooi HC, Hounsell EF, Lax I, et al. The carbohydrate specificities of the monoclonal antibodies 29.1, 455 and 3 C1B12 raised against the epidermal growth factor receptor of A431 cells. *Biosci Rep* 5:83-94, 1985.
59. Sunada H, MacLeod CL, **Mendelsohn J**. A direct radioimmunoassay for human epidermal growth factor receptor using ³²P-labeled receptor molecule. *Anal Biochem* 149:438-447, 1985.

60. Taetle R, Rhyner K, Castagnola JM, To D, **Mendelsohn J**. The role of transferrin, Fe and transferrin receptors in myeloid leukemia cell growth: Studies with an anti-transferrin receptor monoclonal antibody. *J Clin Invest* 75:1061-1067, 1985.
61. Taetle R, Castagnola JM, **Mendelsohn J**. Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. *Cancer Res* 46:1759-1763, 1986.
62. Sunada H, Magun B, **Mendelsohn J**, MacLeod CL. Monoclonal antibody against EGF receptor is internalized without stimulating receptor phosphorylation. *Proc Natl Acad Sci USA* 83:3825-3829, 1986.
63. MacLeod CL, Luk A, Castagnola JM, Cronin M, **Mendelsohn J**. EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells. *J Cell Physiol* 127:175-182, 1986.
64. Santon JB, Cronin MT, MacLeod CL, **Mendelsohn J**, Masui H, Gill GN. Effects of EGF receptor concentration on tumorigenicity of A431 cells in nude mice. *Cancer Res* 46:4701-4705, 1986.
65. Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, **Mendelsohn J**. Expression of EGF receptor in human cultured cells and tissues: Relationship to cell lineage and stage of differentiation. *Cancer Res* 46:4726-4731, 1986.
66. Masui H, Morayama T, **Mendelsohn J**. Mechanism of antitumor activity in mice for anti-EGF receptor monoclonal antibodies with different isotypes. *Cancer Res* 46:5592-5598, 1986.
67. Yu AL, **Mendelsohn J**, Matsumoto SS. Induction of complete remission in T-cell acute lymphoblastic leukemia with doxycoformycin and 9-beta-D arabinofuranosyladenine. *Adv Exp Med Biol* 195: PtA.491-496, 1986.
68. Sobol RE, Astarita RW, Hofeditz C, et al. EGF receptor expression in human lung carcinomas defined by a monoclonal antibody. *J Natl Cancer Inst* 79:403-407, 1987.
69. Castagnola J, MacLeod C, Sunada H, **Mendelsohn J**, Taetle R. Effects of epidermal growth factor on transferrin receptor phosphorylation and surface expression in malignant epithelial cells. *J Cell Physiol* 132:492-500, 1987.
70. **Mendelsohn J**, Masui H, Goldenberg A. Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking on autocrine pathway. *Trans Assoc Am Physicians C*:173-178, 1987.
71. Vollmar AM, Banker DE, **Mendelsohn J**, Herschman HR. Toxicity of ligand and antibody-directed ricin A chain conjugates recognizing the epidermal growth factor receptor. *J Cell Physiol* 131:418-425, 1987.

72. Palombella VJ, **Mendelsohn J**, Vilcek J. Mitogenic action of tumor necrosis factor in human fibroblasts: interaction with epidermal growth factor and platelet-derived growth factor. *J Cell Physiol* 135:23-31, 1988.
73. Masui H, Kamrath H, Apell G, Houston LL, **Mendelsohn J**. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to ricin-A chain. *Cancer Res* 49:3482-3488, 1989.
74. Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, **Mendelsohn J**. EGF receptor overexpression and localization of nude mouse xenografts using ¹¹¹Indium labeled anti-EGF receptor monoclonal antibody. *J Natl Cancer Inst* 81:1616-1625, 1989.
75. Kumar R and **Mendelsohn J**. Role of the 2'-5'-oligoadenylate synthetase in gamma interferon-mediated growth inhibition of A431 cells. *Cancer Res* 49:5180-5184, 1989.
76. Ennis BW, Valverius EM, Lippman ME, et al. Monoclonal anti-EGF receptor antibodies inhibit the growth of malignant and non-malignant human mammary epithelial cells. *Mol Endocrinol* 3:1830-1838, 1989.
77. Chen LL, Dean A, Jenkinson T, **Mendelsohn J**. Effect of transforming growth factor- β 1 on proliferation and induction of hemoglobin accumulation in K-562 cells. *Blood* 74:2368-2375, 1989.
78. Manni A, Wright C, Badger B, et al. Role of transforming growth factor- related peptides in the autocrine/paracrine control of experimental breast cancer growth in vitro by estradiol, prolactin and progesterone. *Breast Cancer Res Treat* 15:73-83, 1990.
79. Bates SE, Valverius EM, Ennis BW, et al. Expression of the TGF /EGF Receptor Pathway in normal human breast epithelial cells. *Endocrinology* 126:596-607, 1990.
80. Sunada H, Yu P, Peacock JS, **Mendelsohn J**. Modulation of tyrosine serine and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by anti-receptor monoclonal antibody. *J Cell Physiol* 142:284-292, 1990.
81. Ciardiello F, McGeady ML, Kim N, et al. TGF expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene and overexpression of the TGF cDNA leads to transformation. *Cell Growth Differ* 1:407-420, 1990.

82. **Mendelsohn J.** Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents. *J Steroid Biochem Mol Biol* 37:889-892, 1990.
83. Kumar R and **Mendelsohn J.** Growth regulation of A431 cells. Modulation of expression of transforming growth factor- mRNA and 2',5'-oligoadenylate synthetase activity. *J Biol Chem* 265:4578-4582, 1990.
84. Divgi CR, Welt C, Kris M, et al. Phase I and imaging trial of indium-111 labeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. *J Natl Cancer Inst* 83:97-104, 1991.
85. Kumar R, Shepard HM, **Mendelsohn J.** Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. *Mol Cell Biol* 11:979-986, 1991.
86. Van de Vijver M, Kumar R, **Mendelsohn J.** Ligand-induced activation of A431 cell EGF receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. *J Biol Chem* 266:7503-7508, 1991.
87. Sunada H, Peacock J, **Mendelsohn J.** Ligand induced internalization of epidermal growth factor receptors by A431 decreases at high cell densities in culture. *Growth Factors* 5:45-55, 1991.
88. Hofer DR, Sherwood ER, Bromberg WD, **Mendelsohn J,** Lee C, Koslowski JM. The functional role of transforming growth factor alpha as an autocrine growth factor in androgen-independent human prostatic carcinoma. *Cancer Res* 51:2780-2785, 1991
89. Goldkorn T, Dressler KA, Muindi J, Radin NS, **Mendelsohn J,** Menaldino D, Liotta D, Kolesnick RN. Ceramide stimulates epidermal growth factor receptor phosphorylation in A431 human epidermoid carcinoma cells: evidence that ceramide mediates sphingosine action. *J Biol Chem* 266:16092-16097, 1991
90. Goldkorn T, **Mendelsohn J.** Transforming growth factor β modulates growth and phosphorylation of epidermal growth factor receptors in A431 cells. *Cell Growth Differ* 3:101-109, 1992.
91. Klein SB, **Mendelsohn J,** Fisher GJ, Voorhees JJ, Elder JT. TGF- α autoinduction is stimulated via the EGF receptor tyrosine kinase and is independent of PCK. *J Cell Physiol* 151:326-336, 1992.
92. Atlas I, **Mendelsohn J,** Baselga J, Masui H, Fair WR, Kumar R. Growth regulation of human renal carcinoma cells: Role of transforming growth factor- α . *Cancer Res* 52:3335-3339, 1992.

93. Galberoglio C, Cordon-Cardo C, Sorvillo J, Casper ES, Houghton AN, **Mendelsohn J**, Brennan MF. Expression of epidermal growth factor receptor and transforming growth factor alpha in human myogenic sarcomas. *J Clin Exp Cancer Res* 11 (2):83-91, 1992.
94. Karnes WE Jr., Walsh JH, Wu SV, Kim RS, Martin MG, Wong HC, **Mendelsohn J**, Gazdar AF, Cuttitta F. Autocrine stimulation of EGF receptors by TGF-regulates autonomous proliferation of human colon cancer cells. *Gastroenterology* 102:474-485, 1992.
95. Fong C-J, Sherwood ER, **Mendelsohn J**, Lee C, Kozlowski JM. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. *Cancer Res* 52:5887-5892, 1992.
96. Masui H, Castro L, **Mendelsohn J**. Consumption of epidermal growth factor by A431 cells: Evidence for receptor recycling. *J Cell Biol* 120:85-93, 1993.
97. Chen L, Narayana, R, Hibbs MS, Benn PA, Clawson ML, Lu G, Rhim JS, Greenberg BB, **Mendelsohn J**. Altered epidermal growth factor signal transduction in activated Ha-Ras-transformed human keratinocytes. *Biochem Biophys Res Commun* 193:167-174, 1993.
98. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, **Mendelsohn J**. Anti-tumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. *J Natl Cancer Inst* 85 (16): 1327-1333, 1993.
99. Chen LL, Gansbacher B, Gilboa E, Taetle R, Oval J, Hibbs MS, Huang C-K, Clawson ML, Bilgrami S, Schlessinger J, **Mendelsohn J**. Retroviral gene transfer of epidermal growth factor receptor into HL60 cells results in a partial block of retinoic acid induced granulocytic differentiation. *Cell Growth Differ* 4:769-776, 1993.
100. Fan Z, Masui H, Atlas I, **Mendelsohn J**. Blockade of epidermal growth factor (EGF) receptor function by bivalent and monovalent fragments of 225 anti-EGF receptor monoclonal antibody. *Cancer Res* 53:4322-4328, 1993.
101. Fan Z, Baselga J, Masui H, **Mendelsohn J**. Antitumor effect of anti-EGF receptor monoclonal antibodies plus cis-Diamminedichloroplatinum on well established A431 cell xenografts. *Cancer Res* 53:4637-4642, 1993.
102. Fan Z, **Mendelsohn J**, Masui H, Kumar R. Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. *J Biol Chem* 268:21073-21079, 1993.

103. Naramura M, Gillies SD, **Mendelsohn J**, Reisfeld RA, Mueller BM. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. *Cancer Immunol Immunother* 37:343-349, 1993.
104. Stampfer MR, Pan CH, Hosoda J, Bartholomew J, **Mendelsohn J**, Yaswen P. Blockage of EGF receptor signal transduction causes reversible arrest of normal and immortal human mammary epithelial cells with synchronous re-entry into the cell cycle. *Exp Cell Res* 208:175-188, 1993.
105. Meyers MB, Yu P, **Mendelsohn J**. Cross-talk between Epidermal growth factor receptor and P-lycoprotein in actinomycin D-resistant chine hamster lung cells. *Biochem Pharmacol* 46:1841-1848, 1993.
106. Naramura M, Gillies SD, **Mendelsohn J**, Reisfeld RA, Mueller BM. Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. *Immunol Lett* 39:91-99, 1994.
107. Kumar R, **Mendelsohn J**. Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor- α . *Anticancer Res* 14:1001-1008, 1994.
108. Fan Z, Lu Y, Wu X, **Mendelsohn J**. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. *J Biol Chem* 269:27595-27602, 1994.
109. Sturgis E, Sacks P, Masui H, **Mendelsohn J**, Schantz S. Effects of anti-epidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. *Otolaryngol Head Neck Surg* 111:633-643, 1994
110. Rubin M, Fenig E, Rosenauer A, et al. 9-cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. *Cancer Res* 54:6549-6556, 1994.
111. Baselga J and **Mendelsohn J**. The epidermal growth factor receptor as a target for therapy in breast carcinoma. *Breast Cancer Res Treat* 29: 129-138, 1994.
112. Ciardiello F, Damiano V, Bianco C, di Isernia G, Ruggiero A, Caraglia M, Tagliaferri P, Baselga J, **Mendelsohn J**, Bianco AR, Tortora G. Synergistic antiproliferative effect of 8-Cl-cAMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. *Clinical Cancer Research* 1:161-167, 1995.

113. Wu X, Fan Z, Masui H, Rosen N, **Mendelsohn J**. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. *J Clin Invest* 95:1897-1905, 1995.
114. Scher HI, Sarkis A, Reuter V, et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor- α in the progression of prostatic neoplasms. *Clin Cancer Res* 1:545-550, 1995.
115. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, **Mendelsohn J**, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor- α in the progression of prostatic neoplasms. *Clinical Cancer Research* 1:545-550, 1995.
116. Fan Z, Lu Y, Wu X, DeBlasio A, Koff A, **Mendelsohn J**. Prolonged induction of p21^{Cip1/WAF1}/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. *J Cell Biol* 131:235-242, 1995.
117. Korutla L, Cheung JY, **Mendelsohn J**, Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. *Carcinogenesis* 16:1741-1745, 1995.
118. Goldstein NI, Prewett M, Zuklys K, Rockwell P, **Mendelsohn J**. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. *Clin Cancer Res* 1:1311-1318, 1995.
119. Soos T, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B, **Mendelsohn J**, Koff A. Formation of p27-CDK complexes during the human mitotic cell cycle. *Cell Growth & Differentiation* 7:135-146, 1996.
120. Baselga J, **Mendelsohn J**, Kim YM, Pandiella A. Autocrine regulation of membrane transforming growth factor- α cleavage. *J Biol Chem* 271:3279-3284, 1996.
121. Normanno N, Bianco C, Damiano V, deAngelis E, Selvam MP, Grassi M, Magliulo G, Tortora G, Bianco AR, **Mendelsohn J**, Salomon DS, Ciardiello F. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. *Clinical Cancer Research* 2:601-609, 1996.
122. Baselga J, Tripathy D, **Mendelsohn J**, et al. Phase II study of weekly intravenous recombinant humanized anti-p185^{HER2} monoclonal antibody in patients with HER2/*neu*-overexpressing metastatic breast cancer. *J Clin Oncol* 14:737-744, 1996.

123. Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, **Mendelsohn J**. Involvement of p27^{KIP1} in G₁ arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. *Oncogene* 12:1397-1403, 1996.
124. Reisfeld RA, Gillies SD, **Mendelsohn J**, Varki NM, Becker JC. Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic *nu/nu* mice by an antibody-lymphotoxin fusion protein. [Advances in Brief] *Cancer Res* 56:1707-1712, 1996.
125. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, **Mendelsohn J**. Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27^{Kip1} and induces G₁ arrest in prostatic cancer cell line DU145. [Advances in Brief] *Cancer Res* 56:3666-3669, 1996.
126. Ciardiello F, Damiano V, Bianco R, Bianco C, Fortanini G, De Laurentiis, M, De Placido S, **Mendelsohn J**, Bianco, AR and Tortora G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. *J Natl Cancer Inst* 88:1770-1776, 1996.
127. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, **Mendelsohn J**, Scher HI, Goldstein NI. The biological effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. *Journal of Immunotherapy with Emphasis on Tumor Immunology* 19:419-427, 1996.
128. Becker JC, Pancook JD, Gillies SD, **Mendelsohn J**, Reisfeld RA. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. *Proc Natl Acad Sci USA* 93: 2702-2707, 1996.
129. Wang H, Rubin M, Fenig E, DeBlasio A, **Mendelsohn J**, Yahalom J, Wieder R. Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G₁ events. *Cancer Res* 57: 1750-1757, 1997.
130. Fan Z, Shang BY, Lu Y, Chou J-L, **Mendelsohn J**. Reciprocal changes in p27^{Kip1} and p21^{Cip1} in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors [Advances in Brief]. *Clin Cancer Res* 3:1943-1948, 1997.
131. Bos M, **Mendelsohn J**, Kim Y-M, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. *Clin Cancer Res* 3:2099-2106, 1997.
132. Hu G, Liu W, **Mendelsohn J**, et al. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. *J Natl Cancer Inst* 89:1271-1276, 1997.

133. Bandyopadhyay D, Mandal M, Adam L, **Mendelsohn J**, Kumar R. Physical interaction between EGF receptor and DNA-protein kinase in mammalian cells. *J Biol Chem* 273:1568-1573, 1998.
134. Mandal M, Adam L, **Mendelsohn J**, Kumar R. Nuclear targeting of Bax during epidermal growth factor receptor-induced apoptosis in colorectal cancer cells. *Oncogene* 17:999-1007, 1998.
135. Baselga J, Norton L, Albanell J, Kim Y-M, **Mendelsohn J**. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. *Cancer Res* 58:2825-2831, 1998.
136. Ciardiello F, Caputo R, Bianco R, Dami V, Pomatico G, Pepe S, Bianco AR, Agrawal S, **Mendelsohn J**, Tortora G. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. *J Natl Cancer Inst*, 90: 1087-1094, 1998.
137. Bromberg JF, Fan Z, Brown C, **Mendelsohn J**, Darnell Jr JE. Epidermal growth factor-induced growth inhibition requires Stat1 activation. *Cell Growth Differ* 9:505-512, 1998.
138. Dean GS, Pusztai L, Xu FJ, O'Briant KS, DeSombre K, Conaway M, Boyer CM, **Mendelsohn J**, Bast Jr, RCB. Cell surface density of p185c-erbB-2 determines susceptibility to anti-p185c-erbB-2 -ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170EGFR-RTA in ovarian cancer cells. *Clin Cancer Res*, 4: 2545-2550, 1998.
139. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, **Mendelsohn J**, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3kinase. *J Biol Chem* 273:28238-28246, 1998.
140. Vadlamudi R, Mandal M, Adam L, Bandyopadhyay D, Steinbach G, **Mendelsohn J**, Kumar R. Regulation of cyclooxygenase-2 by HER2 pathway. *Oncogene*, 18: 305-314, 1998.
141. Bast Jr RC, Pusztai L, Kerns BJ, MacDonald JA, Jordan P, Daly L, Boyer CM, **Mendelsohn J**, Berchuck A. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. *Hybridoma*, 17: 313-321, 1998.
142. Vadlamudi R, Adam L, Talukder A, **Mendelsohn J**, Kumar R. Serine phosphorylation of paxillin by heregulin-β1: Role of p38 mitogen activated protein kinase. *Oncogene* 18:7253-7264, 1999.

143. Ye D, **Mendelsohn J**, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. *Oncogene* 18:731-738, 1999.
144. Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, Agrawal S., **Mendelsohn J**, Ciardiello F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. *Clin Cancer Res*, 5: 875-881, 1999.
145. Ye D, **Mendelsohn, J**, Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. *Clin Cancer Res* 5:2171-2177, 1999.
146. Chou J-L, Fan Z, DeBlasio T, Koff A, Rosen N, **Mendelsohn J**. Constitutive overexpression of cyclin-D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. *Breast Cancer Res Treat* 55:267-283, 1999.
147. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, **Mendelsohn J**, Bianco AR, Tortora G. Antitumor activity of sequential treatment with Topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. *Clin Cancer Res*, 5: 909-916, 1999.
148. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz Cc, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous trastusumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. *Semin Oncol*, 26: 78-83, 1999.
149. Vadlamudi R, Mandal M, Adam L, Steinbach G, **Mendelsohn J.**, Kumar R. Regulation of Cyclooxygenase-2 pathway by HER2 receptor. *Oncogene* 18:306-314, 1999.
150. Vadlamudi R, Adam L, Talukder A, **Mendelsohn J.**, Kumar R. Serine phosphorylation of paxillin by heregulin- β 1: role of p38 mitogen activated protein kinase. *Oncogene* 18:7253-7264, 1999.
151. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang, K, **Mendelsohn, J**, Fan Z. *In vivo* enhancement of tumor radioresponse by C225 anti-epidermal growth factor receptor antibody. *Clin Cancer Res*, 6: 701-708, 2000.
152. Baselga J, Pfister D, Cooper MR, Cohen R, Burtneess B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnet K, Anderson V, Waksal H, **Mendelsohn J**. Phase I

- studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. *J Clin Oncol*, 18: 904-914, 2000.
153. Fang M, Liu B, Schmidt J, Lu Y, **Mendelsohn J**, Fan Z. Involvement of p21^{Waf1} in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells. *Anticancer Res* 20:103-111, 2000.
 154. Schmidt M, Lu Y, Liu B, Fang M, **Mendelsohn J**, Fan Z. Differential modulation of paclitaxel-mediated apoptosis by p21^{Waf1} and p27^{Kip1}. *Oncogene* 19:2423-2429, 2000.
 155. Liu B, Fang M, Schmidt M, Lu Y, **Mendelsohn J**, Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. *Br J Cancer* 82:1991-1999, 2000.
 156. Wosikowski K, Silverman JA, Bishop P, **Mendelsohn J**, Bates SE. Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. *Biochim Biophys Acta* 1497:215-226, 2000.
 157. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, **Mendelsohn J**, Tortora G. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. *Clin Cancer Res*, 6: 3739-3747, 2000.
 158. Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, **Mendelsohn J**, De Placido S, Bianco AR, ciardiello F. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. *Clin Cancer Res*, 6: 4343-4350, 2000.
 159. Bagheri-Yarmand R, Vadlamudi R, Wang R, **Mendelsohn J**, Kumar R. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta 1-mediated angiogenesis. *J Biol Chem* 275:39451-39457, 2000.
 160. Schmidt M, Lu Y, Liu B, Fang M, **Mendelsohn J**, Fan Z. Differential modulation of paclitaxel-mediated apoptosis by p21^{Waf1} and p27^{Kip1}. *Oncogene*, 19: 2423-2429, 2000.
 161. Madal M, Vadlamudi R, Nguyen D, Wang R, costa L, Bagheri-Yarmand R, **Mendelsohn J**, Kumar R. Growth factors regulation of heterogeneous nuclear ribonucleoprotein expression and functions. *J. Biol. Chem.*, 276: 9699-9704, 2001.

162. Talukder AH, Jorgensen HF, Mandal M, Mishra SK, Fadlamudi RK, Clark BF, **Mendelsohn J**, Kumar R. Regulation of elongation factor-1 alpha expression by growth factors and anti-receptor blocking antibodies. *J Biol Chem*, 276: 5636-5642, 2001.
163. Ciardiello F, Caputo R, Troiani T, et al. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. *Int J Cancer* 93:172-178, 2001.
164. Albanell J, Codony-Servat J, Rojo F, Del Campo J, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson R, **Mendelsohn J**, Baselga J. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-EGF receptor treatments. *Cancer Res*, 61 (17): 6500-6510, 2001.
165. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, **Mendelsohn J**, Hong WK. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. *Clin Cancer Res* 7:1204-1213, 2001.
166. Liu B., Fang M., Lu Y., **Mendelsohn J.**, Fan Z. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. *Oncogene* 20:1913-1922, 2001.
167. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, **Mendelsohn J**, Fan Z. HER2/PI-3/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. *Oncogene* 22:3205-3212, 2003.
168. Luwor, LB, Yang L, Xinqun L, **Mendelsohn J**, Fan Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. *Oncogene* 24:4433-4441, 2005.

Invited Articles

1. Sell S, **Mendelsohn J**. Transfer of specific immunity with RNA: a review. *Arch Pathol Lab Med* 102:217-222, 1978.

2. Taetle R, To D, **Mendelsohn J**. In vitro sensitivity to steroid hormones and cytotoxic agents of normal and malignant lymphocyte colony-forming cells. *Cancer Res* 43:3553-3558, 1983.
3. Gabrilove J and **Mendelsohn J**. Growth factors in human cancer. *Curr Opin Oncol* 2:163-170, 1990.
4. **Mendelsohn J**. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. *Sem Cancer Biol* 1:339-344, 1990
5. Kumar R and **Mendelsohn J**. Polypeptide growth factors in the regulation of human tumor cell proliferation. *Curr Opin Oncol* 3:70-74, 1991.
6. Baselga J and **Mendelsohn J**. The epidermal growth factor receptor as a target for therapy in breast carcinoma. *Breast Cancer Res Treat* 29:127-138, 1994.
7. Katzenellenbogen JA, Coleman RE, Hawkins RA, Krohn KA, Larson SM, **Mendelsohn J**, Osborne CK, Piwnicka-Worms D, Reba RC, Siegel BA, Welch MJ, Shtern F. Tumor receptor imaging: Proceedings of the National Cancer Institute Workshop, review of current work, and prospective for further investigations. [Meeting Report] *Clin Cancer Res* 1:921-923, 1995.
8. Slovin SF, Livinston PO, Rosen N, Sepp-Lorenzino L, Kelly WK, **Mendelsohn J**, Scher HI. Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach [Review]. *Semin Oncol* 23:41-48, 1996.
9. **Mendelsohn J**. Innovative care, when standard care doesn't work, and in all situations the highest quality care [Invited Special Interview]. In: *Cancer Centers Around the World* 1(2):3-5, 1996.
10. Rusch V, **Mendelsohn J**, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors [Review]. *Cytokine and Growth Factor Reviews* 7:133-141, 1996.
11. Baselga J, **Mendelsohn J**. Type I receptor tyrosine kinases as targets for therapy in breast cancer. *Journal of Mammary Gland Biology and Neoplasia* 2:165-174, 1997.
12. **Mendelsohn J**. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. *Clin Cancer Res* 3:2703-2707, 1997.
13. Fan Z, **Mendelsohn J**. Therapeutic application of anti-growth factor receptor antibodies. *Curr Opin Oncol* 10:67-73, 1998.

14. **Mendelsohn J.** Book Review: Matters of life and death: Perspectives on public health, molecular biology, cancer, and the prospects for the human race. *Nature Med*, 4:465-466, 1998.
15. **Mendelsohn J.** EGF receptor blockade as anticancer therapy. *Cancer Research Therapy and Control* 7:195-197, 1998.
16. **Mendelsohn J.** Blockade of receptors for growth factors: An anticancer therapy. The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. *Clin Cancer Res* 6:747-753, 2000.
17. **Mendelsohn J.** 1999 Jeremiah Metzger Lecture. Targeted cancer therapy. *Trans Am Clin Climatol Assoc* 111:95-110, 2000.
18. **Mendelsohn J., Dinney C.** The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anti-cancer therapy. *J Urol* 165:1152-1157, 2001.
19. **Mendelsohn J., Baselga J.** The EGF Receptor Family as Targets for Cancer Therapy. *Oncogene* 19:6550-6565, 2000.
20. **Mendelsohn J.** The Epidermal Growth Factor Receptor as a Target for Cancer Therapy: A Review. *Endocrine-Related Cancer* 8:3-9, 2001.
21. **Mendelsohn J.** Epidermal growth factor receptor blockade as anticancer therapy. *Amer Soc Clin Oncol 2001 Educational Book* pp. 39-41, 2001
22. **Mendelsohn J.** David A. Karnofsky Award Lecture. Targeting the epidermal growth factor receptor for cancer therapy. *J Clin Oncol* 20(18s):1s-13s, 2002
23. **Mendelsohn J.** Antibody mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. *Cancer Immunol Immunother* 52: 342-346, 2003
24. **Mendelsohn J and Baselga J:** Status of EGF-receptor antagonists in the biology and treatment of cancer. *J Clin Oncol (Biology of Neoplasia series)*. 21: 2787-2799, 2003
25. **Mendelsohn J and Baselga J:** EGFR targeting in cancer. *Seminars in Oncology*. In Press 2006

Editorials

1. **Mendelsohn J.** Immunotoxins: Prospects and Problems. [Editorial]. *J Clin Oncol* 9:2088-2090, 1992.

2. **Mendelsohn, J** and Fan, Z. Epidermal growth factors receptor family and chemosensitization [Editorial]. *J Natl Cancer Inst* 89: 341-343, 1997.
3. **Mendelsohn J.** Use of an Antibody to Target Geldanamycin. [Editorial]. *J Natl Cancer Inst.* 92:1549-1551, 2000.
4. **Mendelsohn J.** The cooperative group bulletin board. [Editorial]. *Clin Cancer Res* 7:1107, 2001.
5. **Mendelsohn J.** Moving discovery into clinical practice. [Editorial] *Clin Cancer Res* 10:8129, 2004.

Abstracts

(Last five years)

1. Chou J-L, Moasser J, Kohl NE, Gibbs JB, Oliff A, **Mendelsohn J**, Sepp-Lorenzino L, Rosen M. The farnesyl transferase inhibitor (FTI) induces G1 arrest in ras-transformed human mammary epithelial cells in combination with epidermal growth factor (EGF) receptor blockade. *Proc Annu Meet Am Assoc Cancer Res*, 38:A426, 63, 1997.
2. Falcey J, Pfister D, Cohen R, Cooper M, Burtness B, **Mendelsohn J**, Waksal H. A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients (pts) with head and neck or lung carcinomas. *Proc Annu Meet Am Soc Clin Oncol*, 16: A1364, 383a, 1997.
3. Fan Z, Koff A, Lu Y, Wu X, Peng D, Chou J-L, **Mendelsohn J**. P27 and p21 from the Kip-Cip family of CDK inhibitors arrest cell cycle traversal. *Proc Annu Meet Am Assoc Cancer Res*, 38:A3332, 497, 1997.
4. Hu G, Lui W, **Mendelsohn J**, Ellis L, Radinsky R, Andreef M, Deisseroth A. Proliferation of cervical cancer cell lines in vitro is dependent on epidermal growth factor receptor levels which can be down regulated by decreases in the expression of the E6/E7 transforming proteins of the integrated human papilloma virus. *J Invest Med*, 45(3), 263A, 1997.
5. **Mendelsohn J** and Fan Z. EGF receptor blockade in the treatment of prostate cancer. 5th Annual Genitourinary Oncology Conference, "Advances in the Biology and Therapy of Prostate Cancer," Houston, TX, 1997.
6. **Mendelsohn J.** Receptor inhibition by antibody as anticancer therapy. SOMPS-7th International Congress on Anti-Cancer Treatment, Paris, France, 1997.

7. **Mendelsohn J.** Receptor inhibition by antibody as anticancer therapy. UICC Study Group Meeting on Basic and Clinical Cancer Research, "Mechanisms of Growth Factor and Hormone Insensitivity," Woods Hole, MA, 1997.
8. **Mendelsohn J.** Receptor inhibition by antibody as anticancer therapy. Program and Abstracts – M. D. Anderson Cancer Center's 50th Annual Symposium on Fundamental Cancer Research "Molecular Determinants of Cancer Metastasis," 47-49, 1997.
9. Peng D, Fan Z, Lu Y, DeBlasio T, Sher H, and **Mendelsohn J.** Regulation of p21^{WAF1/CIP1} transcription by peidermal growth factor in human squamous carcinoma cell line A431. Proc Annu Meet Am Assoc Cancer Res 38:2329, 347, 1997.
10. Slovin SF, Kelly WK, Cohen R, Cooper M, Malone T, Weingard K, Waksal H, Falcey J, **Mendelsohn J**, Scher HI. Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOC) in androgen-independent (AI) prostate cancer (PC): results of a phase Ib/Iia study. Proc Annu Meet Am Soc Clin Oncol 16:A1108, 311a, 1997.
11. Ciardiello F, Caputo R, Bianco R, Bianco R, Damiano V, Pomatico G, Pepe S, Bianco AR, Agrawal S, **Mendelsohn J**, Tortora G. Cooperative inhibition of human renal cancer cell growth by treatment with an anti-epidermal growth factor receptor (EGFR) monoclonal antibody and a mixed backbone antisense oligonucleotide targeting type I protein kinase A (PKAI). Proc Annu Meet Am Assoc Cancer Res 39: A445, 65, 1998.
12. **Mendelsohn J.** Blockade of signal transduction as anti-cancer therapy. 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, June 16-19, 1998.
13. **Mendelsohn J.** Targeting growth factor receptors. 41st Annual Clinical Conference – New Frontiers in Research and Treatment of Aerodigestive Tract Cancer, 105-105, 1998.
14. Perez-Soler R, Shid DM, Donato N, Radinsky R, Khuri F, Glisson BS, Shin H, Matsumoto T, Lawhorn K, Waksal H, Hong WK, **Mendelsohn J.** Tumor studies in patients with head and neck cancer treated with humanized anti-epidermal growth factor (EGFR) monoclonal antibody C225 in combination with cisplatin. Proc Annu Meet Am Soc Clin Oncol 17:A1514, 393a, 1998.
15. Schumacher G, Fan Z, **Mendelsohn J**, and Roth JA. An adenovirus vector expressing wildtype p53 (Ad-p53) upregulates the EGF receptor and enhances growth inhibition of human breast cancer cell line when combined with anti-EGF receptor mAb C225. Proc Annu Meet Am Assoc Cancer Res 39:A2850, 419, 1998.

16. Ye D, **Mendelsohn J**, Lu Y, and Fan Z. The growth of OVCA420 ovarian cancer cells is inhibited by both anti-EGF receptor mAb 225 and anti-HER2 mAb 4D5 in association with increased expression of cyclin-dependent kinase inhibitor p27^{Kip1}. Proc Annu Meet Am Assoc Cancer Res 39:A1687, 246-247, 1998.
17. Adam L, Vadlamudi R, **Mendelsohn J**, and Kimar R. Regulation of metastatic potential of breast cancer cells by human EGF receptor family members. Proc Annu Meet Am Assoc Cancer Res 40:A3428, 520, 1999.
18. Chou JL, Moasser M, Sepp-Lorenzino L, **Mendelsohn J**, Norton L, and Rosen N. Farnesyltransferase inhibitor (FTI) and EGF receptor (EGFR) blockade induced a synergistic G1 arrest in H-Ras-transformed human breast epithelial cells. Proc Annu Meet Am Assoc Cancer Res 40:A1987, 299, 1999.
19. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, **Mendelsohn J**, Bianco AR, Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Proc Annu meet Am Assoc Cancer Res 40: A155, 23, 1999.
20. Fang M, Liu B, **Mendelsohn J**, and Fan Z. EGF can act as a survival factor for Taxol-induced apoptosis. Proc Annu Meet Am Assoc Cancer Res 40:A2155, 325, 1999.
21. Fang m, Liu B, Lu Y, **Mendelsohn J**, and Fan Z. Inhibition of Paclitaxel-induced p34cdc2 kinase premature activation and apoptosis by EGF in MDA468 human breast carcinoma cells. Proc Annu Meet Am Assoc Cancer Res 40:A2154, 325, 1999.
22. Hallin P, Madden T, Fan Z, **Mendelsohn J**, and Chiao P. Anti-growth factor receptor monoclonal antibodies enhance the activity of 5-FU in human pancreatic cancer cell lines. Proc Annu Meet Am Assoc Cancer Res 40:A2645, 400, 1999.
23. **Mendelsohn J**, Shin DM, Donato N, Khuri F, Radinsky R, Glisson BS, Shin HJ, Metz E, Pfister D, Perez-Soler R, Lawhorn K, Matsumoto T, Gunnett K, Falcey J, Waksal H, Hong WK. A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC). Proc Annu Meet Am Soc Clin Oncol 18:A1502, 389a, 1999.
24. **Mendelsohn J**. Blockade of receptors for growth factors as anti-cancer therapy. Proc Annu Meet Am Assoc Cancer Res 40:743-744, 1999.
25. Norton L, Slamon D, Leyland-Jones B, Wolter J, Fleming T, Eirmann W, Baselga J, **Mendelsohn J**, Bajamonde A, Ash M, Shak S. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal

- antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol 18: A483, 127a, 1999.
26. Schmidt M, Ye D, Liu B, **Mendelsohn J**, and Fan Z. Inducible ectopic expression of cyclin dependent kinase inhibitors p21^{WAF1} or p27^{KIP1} in tumor cells results in growth arrest at different phases of the cell cycle. Proc Annu Meet Am Assoc Cancer Res 40:A172, 26, 1999.
 27. Ye D, **Mendelsohn J**, and Fan Z. Androgen and EGF downregulate cyclin-dependent kinase inhibitor p27^{Kip1} and co-stimulate proliferation in two newly established prostatic cancer cell lines, MDA Pca 2a and MDA Pca 2b. Proc Annu Meet Am Assoc Cancer Res 40:A182, 27, 1999.
 28. Ye D, Mills G, **Mendelsohn J**, and Fan Z. Differential effects of EGF and Heregulin on reversing growth inhibition mediated by anti-EGF receptor mAb C225 and by anti-HER2 mAb 4D5 (HerceptimTM) in OVCA420 human ovarian cancer cells. Proc Annu Meet Am Assoc Cancer Res 40:A3399, 515, 1999.
 29. Liu B, Fang M, Lu Y, Mills GB, **Mendelsohn J**, Fan Z. EGF inhibits paclitaxel-induced apoptosis in HPV positive Siha human cervical carcinoma cells through a P13K/AKT and MEK/MAPK-independent pathway. Proc Annu Meet Am Assoc Cancer Res 41:A4041, 636, 2000.
 30. Milas L, Mason K, Hunter N, Peterson S, Yamakawa M, Ang K, **Mendelsohn J**, Fan Z. In vivo enhancement of tumor radioresponse by C225 anti-epidermal growth factor receptor antibody. Proc Annu Meet Am Assoc Cancer Res 41:A4508, 709, 2000.
 31. Rubin MS, Shin DM, Pasmantier M, Flacey JW, Paulter VJ, Fetzer KM, Waksal H, **Mendelsohn J**, Hong WK. Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) for patients (pts) with EGF4-positive tumors refractory to or in relapse from previous therapeutic regimens. Proc Annu Meet Am Soc Clin Oncol 19:A1860, 474a, 2000.
 32. Schmidt M, **Mendelsohn J**, and Fan Z. Differential effects of p16^{INK4}, p21^{WAF1}, and p27^{KIP1} on mediating cell cycle arrest and chemosensitivity in A431 and Siha human cancer cells. Proc Annu Meet Am Assoc Cancer Res 41:A2315 (365), 2000.
 33. Schmidt M, **Mendelsohn J**, and Fan Z. Differential roles of p21^{WAF1} and p27^{KIP1} in mediating chemoresistance of cell cycle-specific and nonspecific antineoplastic drugs. Proc Annu Meet Am Assoc Cancer Res 41:A3004, 471, 2000.

34. Wang L, Schmidt M, Wels W, Dinney CP, **Mendelsohn J**, and Fan Z. Antitumor effect of a Her-2 specific antibody-toxin fusion protein on human prostate cancer cells. Proc Annu Meet Am Assoc Cancer Res 41:A4238, 666-667, 2000.
35. Wen X, Li C, Wu Q-P, Charnsagavej C, Wallace S, **Mendelsohn J**, Fan Z. Potentiation of antitumor activity of PG-TXL with anti-EGFR monoclonal antibody C225 in MDA-MB-468 human breast cancer xenograft. Proc Annu Meet Am Assoc Cancer Res 41:A2052, 323, 2000.
36. Liu B, Lu Y, **Mendelsohn J**, and Fan Z. Activation of caspase-8 during anti-EGF receptor mAb 225-induced apoptosis does not involve the Fas-, TNF- or TRAIL-mediated signaling. Proc Annu Meet Am Assoc Cancer Res 42:A236, 440, 2001.
37. **Mendelsohn J**. Inhibition of EGF receptors as anticancer therapy. Durango, Colorado, Keystone Symposia Abstract Book, *Cancer Intervention*, Abstract #3, pg.24, 2001.
38. **Mendelsohn J**. Inhibition of EGF receptors (R) with a monoclonal antibody as anticancer therapy. 12th International Congress on Anti-Cancer Treatment, Paris, France, Abstract #EL-23, pg. 34, 2002.
39. **Mendelsohn J**. Targeted therapy of solid tumors: an idea whose time has come. The Scripps Cancer Center Annual Conference: Clinical Hematology and Oncology 2002, La Jolla, California, pg. 195.
40. Kumar R, Adam L, Mandal M, and **Mendelsohn J**. Anti-invasive action of anti-EGF receptor antibody C225: suppression of focal-adhesion kinase/ β -catenin signaling components. Proc Annu Meet Am Assoc Cancer Res 43:A2879, 581, 2002.
41. **Mendelsohn J**. Inhibition of the HER family in laboratory studies. (Abstract for symposium). Proc Annu Meet Am Assoc Cancer Res 43:Symp 14, 1172, 2002.
42. Peng D, Liu B, Lu Y, Liang K, Jin W, Wu L, Meric F, Cristofanilli M, Hortobagyi G, **Mendelsohn J**, Fan S. Triple combination with STI571 (Gleevec), Trastuzumab (Herceptin) and Cetuximab (IMC-C225): a treatment model for breast cancer through modulation of growth factor receptors and tyrosine kinases signaling. Proc Annu Meet Am Assoc Cancer Res 43:A4194, 846, 2002.
43. Liang K, Jin W, Peng D, Liu B, Lu Y, Wu L, Ang K, Milas L, **Mendelsohn J**, Fan Z. Inhibition of the PI-3K pathway sensitizes breast cancer cells to breast cancer cells to radiation. Proc Annu Meet Am Assoc Cancer Res 43:A5708, 1151, 2002.

44. **Mendelsohn J.** Targeting drugs against cancer: the EGF receptor tyrosine kinase. 17th Meeting of the European Association for Cancer Research (EACR 17), Granada, Spain, June 11, 2002.
45. **Mendelsohn J.** Inhibition of growth factor signaling as anticancer therapy. II ESOC Meeting, Malaga, Spain, June 12, 2002.
46. **Mendelsohn J.** Targeting the EGF receptor in cancer therapy. 1st International symposium on signal transduction modulators in cancer therapy, Amsterdam, The Netherlands, September 23-25, 2002.
47. **Mendelsohn J.** Combining kinase inhibitors with chemotherapy. 14th EORTC-NCI-AACR symposium on “molecular targets and cancer therapeutics.” Frankfurt, Germany, November 19-22, 2002.
48. **Mendelsohn J.** EGFR and Solid Malignancies. 44th Annual Clinical Conference: Molecular Therapeutics for Cancer Metastasis, Houston, Texas, March 18-21, 2003.
49. **Mendelsohn J.** The EGFR family as a target for cancer therapy. Biotherapy of Cancer: From Disease to Targeted Treatment, Munich, Germany, September 10-13, 2003.
50. **Mendelsohn J.** Augmentation of chemotherapy and radiotherapy by EGF receptor inhibition. 45th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Salt Lake City, Utah, October 19-23, 2003.
51. **Mendelsohn J.** Merging medicine with science: the birth of a targeted therapy in cancer. 2004 NHG Annual Scientific Congress, Singapore, October 9-11, 2004.
52. **Mendelsohn J.** Merging medicine with science: the birth of a targeted therapy in cancer. 2004 NHG Annual Scientific Congress, CNIO meeting, Madrid, Spain, November 22, 2004.

Book Chapters

1. Salzman NP and **Mendelsohn J.** Isolation and fractionation of metaphase chromosomes. In *Methods in Cell Physiology*, vol. 3, pp. 227-292. New York: Academic Press, 1968.
2. **Mendelsohn J.** Studies of isolated mammalian metaphase chromosomes. In *The Cell Nucleus*, vol. II, pp. 123-147. New York: Academic Press, 1974.
3. Bernheim JL and **Mendelsohn J.** Kinetics of DNA synthesis and cell proliferation in lymphocyte activation [Workshop Review]. In *Regulatory*

- Mechanisms in Lymphocyte Activation, pp. 479-505. New York: Academic Press, 1977.
4. Bernheim JL, Dorian R, and **Mendelsohn J**. Pitfalls in the lymphocyte proliferation assay: variations in proliferation kinetics and cold thymidine pools. In *Regulatory Mechanisms in Lymphocyte Activation*, pp. 464-466. New York: Academic Press, 1977.
 5. **Mendelsohn J**, Dorian R, Castagnola J, and Bernheim J. Is there gene amplification or other nonduplicative DNA synthesis in human lymphocyte activation? In *Regulatory Mechanisms in Lymphocyte Activation*, pp. 467-469. New York: Academic Press, 1977.
 6. Shifan, TA, Caviles AP Jr., and **Mendelsohn J**. Spontaneous lymphocyte proliferation in Hodgkin's disease. In *Regulatory Mechanisms in Lymphocyte Activation*, pp. 677-679. New York: Academic Press, 1977.
 7. Snyder FF, **Mendelsohn J**, and Seegmiller JE. Adenosine and guanosine metabolism during phytohemagglutinin induced transformation of human lymphocytes. In *Purine Metabolism in Mann-II: Regulation of Pathways and Enzyme Defects*, pp. 441-447. New York: Plenum Press, 1977.
 8. **Mendelsohn J** and Nordberg J. Adenylate cyclase in normal and leukemic human lymphocytes. In *Cell biology and Immunology of Leukocyte Function*, pp. 143-147. New York: Academic Press, 1979.
 9. Bernheim JL and **Mendelsohn J**. Evidence for an against unusual species of DNA in lymphocyte activation. In *Cell Biology and Immunology of Leukocyte Function*, pp. 115-119. New York: Academic Press, 1979.
 10. Vyth-Dreese FA, de Vries JE, and **Mendelsohn J**. Induction and characterization of a T-cell growth factor (TCGF) dependent leukemic T-cell culture. In *Leukemia Markers*, pp. 341-344. New York: Academic Press, 1981.
 11. Green MF, Markman M, and **Mendelsohn J**. Supportive care. In *Cancer Chemotherapy 4*, pp. 472-431. Amsterdam: Elsevier, 1982.
 12. **Mendelsohn J**, Caviles A Jr., and Castagnola J. Proliferation of normal human lymphocytes in serum-free albumin-free medium. In *Growth of Cells in Hormonally-Defined Media*, vol. 9, pp. 677-690. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1982.
 13. **Mendelsohn J** and Green MR. Supportive care. In *Cancer Chemotherapy 5*, pp. 479-491. Amsterdam: Elsevier, 1983.

14. **Mendelsohn J**, Dillman RO, and Royston I. Use of biological response modifiers in the management of cancer. In *Management of Advanced Cancer*, pp. 167-193. Masson Publishing, 1983.
15. **Mendelsohn J**, Caviles A Jr., and Castagnola J. Culture of human lymphocytes in serum-free medium. In *Methods of Serum-Free Culture of Neuronal and Lymphoid Cells*, pp. 207-214. New York: Alan R. Liss, Inc., 1984.
16. Markman M, **Mendelsohn J**, and Green MR. Supportive care. In *Cancer Chemotherapy* 6, pp. 481-490. Amsterdam: Elsevier, 1984.
17. MacLeod CL, Masui H, Trowbridge IS, and **Mendelsohn J**. Monoclonal antibodies directed towards growth-related receptors on human tumors. In *Monoclonal Antibody Therapy of Human Cancer*, pp. 57-83. Boston: Martinus Nijhoff Publishing, 1985.
18. Le A, **Mendelsohn J**, Sato GH, Sunada H, and MacLeod CL. Receptor processing by monoclonal antibodies to the EGF receptor. In *Growth and differentiation of Cells in Defined Environments*, pp. 303-306. Heidelberg: Springer-Verlag, 1985.
19. **Mendelsohn J**. Principles of neoplasia. In *Harrison's Principles of Internal Medicine*, 11th ed, pp. 421-454. New York: McGraw Hill, 1987.
20. **Mendelsohn J**. Epidermal growth factor receptors as potential targets for antitumor therapy with monoclonal antibodies. In *Growth Regulation of Cancer*, pp. 169-173. New York: Alan R. Liss, Inc., 1988.
21. **Mendelsohn J**, Masui H, Sunada H, and MacLeod C. Monoclonal antibodies against the receptor for epidermal growth factor as potential anticancer agents. In *Cellular and Molecular Biology of Tumors and Potential Clinical Applications*, pp. 307-312. New York: Alan R. Liss, Inc., 1988.
22. **Mendelsohn J**. Workshop: antibodies and other biological response modifiers as preventative, diagnostic, and therapeutic agents. In *Cellular and Molecular Biology of Tumor and Potential Clinical Applications*, pp. 313-315. New York: Alan R. Liss, Inc., 1988.
23. **Mendelsohn J**. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. In *Monoclonal Antibody Therapy*, vol. 45, pp. 147-160. Basel, Switzerland: Karger Publications, 1988.
24. **Mendelsohn J**. Clinical perspective – cell-surface receptor proteins for growth factors as cancer markers: epidermal growth factor receptor and HER-2/*neu* protein. In *Molecular Diagnostics of Human Cancer*, pp. 343-345. New York: Cold Spring Harbor Laboratory, 1989.

25. **Mendelsohn J.** Potential clinical applications of anti-EGF receptor monoclonal antibodies. In *Molecular Diagnostics of Human Cancer*, pp. 359-362. New York: Cold Spring Harbor Laboratory, 1989.
26. **Mendelsohn J.** Antibodies to growth factors and receptors. In *Biologic Therapy of Cancer*, 1st ed., pp. 601-612. Philadelphia: J.B. Lippincott, Co., 1991.
27. **Mendelsohn J.** Principles of neoplasia. In *Harrison's Principles of Internal Medicine*, 12 ed., pp. 1576-1587. Washington, DC: McGraw Hill, Inc., 1991.
28. **Mendelsohn J.** Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. In *Biology of and Novel Therapeutic Approaches for Epithelial Cancers of the Aerodigestive Tract*, pp. 125-131, 1992.
29. **Mendelsohn J.** Monoclonal antibodies against receptors for cytokines as potential anticancer agents. In *Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis, and Therapy*, pp. 195-200. Oxford University Press, 1993.
30. **Mendelsohn J** and Lippman M. Principles of molecular cell biology of cancer: growth factors. In *Cancer: Principles and Practice of Oncology*, 4th ed, pp. 114-133. Philadelphia: J.B. Lippincott Co., 1993.
31. **Mendelsohn J.** Growth-factor receptors as a target for therapy. In *Lung Cancer*, pp. 364-387. Boston: Blackwell Scientific Publications, 1993.
32. **Mendelsohn J.** Anti-EGF receptor monoclonal antibodies as potential anti-cancer therapy. In *Cancer Treatment An Update*, pp. 17-18. Heidelberg: Springer-Verlag, 1994.
33. Baselga J and **Mendelsohn J.** Receptor blockade with monoclonal antibodies as anti-cancer therapy. In *Pharmacology and Therapeutics*, vol. 64, pp. 127-154. London: Pergamon Press, Elsevier Science Ltd., 1994.
34. **Mendelsohn J.** Principles of neoplasia. In *Harrison's Principles of Internal Medicine*, 13 ed., pp. 1814-1826. Washington, DC: McGraw Hill, Inc., 1994.
35. **Mendelsohn J** and Baselga J. Antibodies to growth factors and receptors. In *Biologic Therapy of Cancer*, 2nd ed. pp, 607-623. Philadelphia: J.B. Lippincott Co., 1995.
36. Baselga J and **Mendelsohn J.** Interaction of biologic agents with chemotherapy. In *Biologic Therapy of Cancer*, 2 ed., pp. 863-875. Philadelphia: J.B. Lippincott Co., 1995.

37. **Mendelsohn J** and Gabrilove J. Growth factors in malignancy. In *The Molecular Basis of Cancer*, pp. 432-459. Philadelphia: W.B. Saunders Co., 1995.
38. **Mendelsohn J**, Fan Z, and Baselga J. Combination therapy with cisplatin and EGF receptor blockade. In *Platinum and Other Metal Coordination Compounds in cancer chemotherapy-2*, pp. 115-163. New York: Plenum Press, 1996.
39. Grant SC, Lynch SA, and **Mendelsohn J**. Growth factors in lung cancer: current status and implications for therapy. In *Growth Factors and Cytokines in Health and Disease*, vol. 3B, Systems, pp. 355-380. Greenwich, CT: Jai Press, 1997.
40. **Mendelsohn J**, Baselga J, Wu X, Peng D, Brown C, Chou J-L, and Fan Z. EGF receptor inhibition by antibody as anticancer therapy. In *EGF Receptor in Tumor Growth and Progression*, pp. 233-251. Heidelberg: Springer-Verlag, 1997.
41. **Mendelsohn J**. Target therapy: the EGF receptor. In *Progress in Cancer therapy*, vol. II. Boston: Blackwell Science, 1997.
42. Perez-Solar R and **Mendelsohn J**. Growth-factor receptors as a target for therapy. In *Lung Cancer*, 2nd ed., pp. 309-341. Malden, MA: Blackwell Science, Inc., 1998.
43. Grant S, Early E, **Mendelsohn J**. Monoclonal Antibodies in the Management of Lung Cancer. In *Monoclonal antibody-based therapy of cancer*, pp. 365. New York, NY: Dekker, 1998.
44. Fan Z and **Mendelsohn J**. Breast cancer therapy using monoclonal antibodies against epidermal growth factor receptor and HER-2. In *Breast Cancer: Molecular Genetics, Pathogenesis and Therapeutics*, pp. 419-436. Totowa, NJ: Humana Press, 1999.
45. Baselga J and **Mendelsohn J**. Monoclonal antibodies directed against growth factor receptors. In *Biologic Therapy of Cancer*, 3rd ed., pp. 475-489. Philadelphia: Lippincott Williams & Wilkins, 2000.
46. **Mendelsohn J**, Baird A, Fan Z, and Markowitz S. Growth factors and their receptors in epithelial malignancies. In *The Molecular Basis of Cancer*, 2nd ed., pp. 137-161. Philadelphia: W.B. Saunders Company, 2001.
47. Herbst R, Onn A, and **Mendelsohn J**. The role of growth factor signaling in malignancy, in Frank DA (ed), *Signal Transduction in Cancer*, The Netherlands, Kluwer Academic Publishers, 2003, pp 19-72.
48. Onn A, **Mendelsohn J**, Herbst RS. Targeting the epidermal growth factor receptor in the clinic. In *Progress in Oncology 2004*, Boston Toronto London Singapore: Jones and Bartlett Publishers, 2004, Vol. IV pp. 73-100.

49. **Mendelsohn J**: Development of a targeted treatment for cancer: the example of C225 (Cetuximab). In *Molecular Targeting in Oncology*, Humana Press, (In Press).

Books

(Edited and written)

1. **Mendelsohn J**, Guest editor. Update VII, New Concepts in Oncology, Harrison's Principles of Internal Medicine. New York: McGraw Hill, 1986.
2. **Mendelsohn J**, Howley P, Liotta L, Israel M, (eds.). *The Molecular Basis of Cancer*. Philadelphia: WB Saunders Co., 1995.
3. **Mendelsohn J**, Howley P, Liotta L, Israel M, (eds.). *The Molecular Basis of Cancer*, 2nd ed. Philadelphia: WB Saunders Co., 2001.